News

For the most recent news and press releases, visit our investor relations website: www.ir.icecure-medical.com

IceCure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the ICE3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) announced that the first peer reviewed article “Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial was published in the Annals of Surgical Oncology with Dr. Richard Fine, MD, FACS, an ICE3 investigator who serves as Program Director of the Breast Surgical Oncology Fellowship and as Director of Research and Education at the West Comprehensive Breast Center in Germantown, TN, as the lead author.

Read More »

IceCure Medical Shares to Begin Trading on Nasdaq Capital Market on August 26, 2021

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that its ordinary shares have been approved for listing on the Nasdaq Capital Market (“Nasdaq”). The Company’s shares will begin trading on Nasdaq on today, August 26, 2021, at market open, under the ticker symbol “ICCM.”

Read More »

What a fantastic #NCoBC2023! Thank you to everyone who stopped by @IceCureMedical’s booth to learn more about #cryoablation for breast tumors with the #ProSense System.

See you next year!

#breastcare #WomensHealth @NCBC_BreastCare

Thank you for 1,000 #Twitter followers! @IceCureMedical is so grateful for every one of you.
We appreciate your support of our #LiquidNitrogen Based #ProSense #Cryoablation #Sytem for optimal tumor destruction.

#interventionalradiology #interventionaloncology #medtwitter

למה אייסקיור הייתה בשבוע האופנה #TLVFashionWeek?

טללית בוסי תל צור שלנו דיברה בפאנל פתרונות בסרטן השד כדי לשתף כיצד מערכת הפרוסנס שלנו משנה את הדרך בה אנו מטפלים במחלה בישראל על ידי קריואבלציה.

לסרטון המלא: http://youtu.be/MThCqWlHVlc

@IceCureMedical @BussiTlalit

Read all about @IceCureMedical 's @BussiTlalit's insights on our participation in #TLVFashionWeek's #BreastCancer panel in this article by @NoCamels!

https://nocamels.com/2023/03/tlv-fashion-week-showcases-breast-cancer-freezing-tech/?fbclid=IwAR2lD0uf2LEMJa-vYIG6Ynvdb7YoQE0yEG2RrMzEdc8mEhnHGYecb99NlfE

IceCure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the ICE3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) announced that the first peer reviewed article “Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial was published in the Annals of Surgical Oncology with Dr. Richard Fine, MD, FACS, an ICE3 investigator who serves as Program Director of the Breast Surgical Oncology Fellowship and as Director of Research and Education at the West Comprehensive Breast Center in Germantown, TN, as the lead author.

Read More »

IceCure Medical Shares to Begin Trading on Nasdaq Capital Market on August 26, 2021

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that its ordinary shares have been approved for listing on the Nasdaq Capital Market (“Nasdaq”). The Company’s shares will begin trading on Nasdaq on today, August 26, 2021, at market open, under the ticker symbol “ICCM.”

Read More »